Crossmark

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

Crossref DOI link: https://doi.org/10.1186/s13058-020-01305-7

Published Online: 2020-06-18

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Roberts, Melyssa S.

Anstine, Lindsey J.

Finke, Viviane S.

Bryson, Benjamin L.

Webb, Bryan M.

Weber-Bonk, Kristen L.

Seachrist, Darcie D.

Majmudar, Parth R.

Keri, Ruth A. http://orcid.org/0000-0002-1640-3088
Funding

Funding for this research was provided by:

National Institutes of Health (R01CA154384, R01CA213843, R01CA206505, P30CA016672, F31CA224809, P30CA043703)

National Cancer Institute (P30CA043703)

U.S. Department of Defense (W81XWH-18-1-0455)
License Information

Text and Data Mining valid from 2020-06-18

Version of Record valid from 2020-06-18
More Information

Article History

Received: 17 March 2020

Accepted: 1 June 2020

First Online: 18 June 2020

Ethics approval and consent to participate

: Not applicable

: Not applicable

: The authors declare that they have no conflicts of interest with the contents of this article.

Document is current

Any future updates will be listed below